SCAD Genetics: Why Heart Attacks in Young Women Need Different Rules

What They Found

Swedish researchers sequenced the exomes of 201 patients with spontaneous coronary artery dissection (SCAD) to hunt for genetic variants. SCAD causes heart attacks primarily in young women without traditional risk factors—no diabetes, normal cholesterol, non-smokers. The study aimed to identify rare genetic variants in known SCAD genes and discover new ones.

Why It Matters

SCAD represents a fundamental blind spot in cardiovascular medicine. We've built our entire risk prediction framework around atherosclerotic disease—plaques that build up over decades in response to metabolic dysfunction. But SCAD is different. The coronary artery literally tears apart spontaneously, often in women under 50 who look metabolically perfect on paper.

This genetic approach matters because it could finally explain why some women develop SCAD while others don't. If specific genetic variants predispose to arterial wall weakness or abnormal vascular remodeling, we need different screening protocols. Current cardiovascular risk calculators are useless for these patients.

The timing is critical too. SCAD often hits during periods of hormonal fluctuation—postpartum, perimenopausal—suggesting genetic variants that interact with estrogen signaling or vascular smooth muscle function. Understanding these pathways could inform hormone replacement therapy decisions and identify high-risk periods.

What I'd Watch For

The sample size of 201 patients is modest for genetic association studies, especially when hunting for rare variants. Without seeing the actual results, I'm concerned about statistical power and replication. Genetic studies need thousands of cases to reliably identify causal variants, not hundreds.

The real test will be whether these findings replicate in other populations and translate into actionable clinical tools. Can we develop a genetic risk score? Do identified variants suggest specific therapeutic targets? Without functional validation of any discovered variants, this remains correlative.

Bottom Line

SCAD genetics could revolutionize how we approach cardiovascular risk in young women, but this study alone won't change clinical practice. We need larger cohorts, functional studies, and ultimately, genetic testing that actually predicts who's at risk before their first dissection.